floxuridine has been researched along with 2',2'-difluoro-2'-deoxyuridine in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 22 (50.00) | 29.6817 |
| 2010's | 20 (45.45) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Edzes, HT; Noordhuis, P; Peters, GJ; Vermorken, JB | 1 |
| Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG | 1 |
| Bacher, N; Hohla, F; Irschick, E; Konwalinka, G; Mühlmann, O; Strasser-Wozak, E; Tiefenthaler, M; Wein, W | 1 |
| Goh, BC; Lee, HS; Noordhuis, P; Peters, GJ; Wang, LZ | 1 |
| Bettinelli, M; Minoia, C; Sottani, C; Zaffaroni, M; Zucchetti, M | 1 |
| Aksoy, Y; Kadioğlu, YY; Yilmaz, B | 1 |
| Buesa, JM; Díaz, A; Esteban, E; Fernández, A; Fra, J; López-Pousa, A; Losa, R; Sierra, M | 1 |
| Fan, Y; Fang, L; Lin, NM; Ma, SL; Zeng, S; Zhong, HJ | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T | 1 |
| Baas, P; Beijnen, JH; Crul, M; Pluim, D; Rademaker-Lakhai, JM; Schellens, JH; Sparidans, RW; van Zandwijk, N | 1 |
| de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Freise, KJ; Martín-Jiménez, T | 2 |
| Dagit, JW; Fisher, JE; Guire, DE; Hassan, I; Kirstein, MN; Remmel, RP; Weller, DR | 1 |
| Beijnen, JH; Rosing, H; Schellens, JH; Thijssen, B; Vainchtein, LD | 1 |
| Caffo, O; D'Incalci, M; Galligioni, E; Marangon, E; Sala, F; Zucchetti, M | 1 |
| Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T | 1 |
| Beijnen, JH; Bolijn, MJ; Govindarajan, R; Ong, FH; Pluim, D; Schellens, JH; Unadkat, JD; van Eijndhoven, MA; Veltkamp, SA | 1 |
| Hollender, J; Kovalova, L; McArdell, CS | 1 |
| Beijnen, JH; Jansen, RS; Rosing, H; Schellens, JH | 1 |
| Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Hollender, J; Kovalova, L; Mcardell, CS; Moser, R; Ort, C; Pazhepurackel, V; Siegrist, H; Weissbrodt, D | 1 |
| Celia, C; Cosco, D; Costante, G; Filetti, S; Fresta, M; Iannone, M; Paolino, D; Puxeddu, E; Racanicchi, L; Russo, D; Trapasso, E | 1 |
| Boezen, HM; de Vries, EG; Groen, HJ; Maring, JG; Maurer, JM; Slijfer, M; Uges, DR; Wachters, FM | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Aelbrecht, K; De Boeck, G; Dyck, J; Guetens, G; Specenier, P; Van den Weyngaert, D; Vermorken, JB; Weyler, J | 1 |
| Benyumov, A; Gurvich, VJ; Kirstein, MN; Lis, LG; Williams, BW | 1 |
| Hodge, LS; Taub, ME; Tracy, TS | 2 |
| Bapiro, TE; Cook, N; Frese, KK; Goldgraben, MA; Griffiths, JR; Jacobetz, MA; Jodrell, DI; Madhu, B; Olive, KP; Richards, FM; Smith, DM; Tuveson, DA | 1 |
| Giovannetti, E; Honeywell, RJ; Peters, GJ | 1 |
| Egawa, S; Kawaguchi, K; Motoi, F; Ohmine, K; Ohtsuki, S; Terasaki, T; Unno, M | 1 |
| Dudek, AZ; Greeno, EW; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Mitra, AK; Skubitz, KM | 1 |
| Chen, H; Fan, B; Fang, S; Lu, Q; Sun, Y; Tang, D; Wei, Y; Yin, J; Yin, X; Zhang, B; Zhang, F | 1 |
| Lee, LB; Ruterbories, KJ; Schmalz, CA; Torchia, J; Wickremsinhe, ER | 1 |
| Honeywell, RJ; Peters, GJ; Ruiz van Haperen, VW; Smid, K; Veerman, G | 1 |
| Bjånes, T; Eide, T; Kamčeva, T; Riedel, B; Schjøtt, J; Svardal, A | 1 |
| Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C | 1 |
| Chen, T; Han, H; Ji, J; Jin, Q; Wang, J; Yin, L | 1 |
| Beijnen, JH; Burgers, JA; Hillebrand, MJX; Rosing, H; Schellens, JHM; van Nuland, M | 1 |
| Beijnen, JH; Derissen, EJB; Huitema, ADR; Rosing, H; Schellens, JHM | 1 |
| Aa, L; Fei, F; Hao, K; Jiang, W; Liu, J; Lu, L; Pei, X; Peng, Y; Sun, Y; Wang, G; Wang, J; Zhen, L | 1 |
| Davis, A; Gibson, EG; Roussel, MF; Stewart, CF; Zhong, B | 1 |
6 trial(s) available for floxuridine and 2',2'-difluoro-2'-deoxyuridine
| Article | Year |
|---|---|
Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cytidine Deaminase; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Exanthema; Fatigue; Floxuridine; Gemcitabine; Genotype; Humans; Japan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Stomatitis; Thrombocytopenia; Treatment Outcome | 2005 |
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Adducts; Dose-Response Relationship, Drug; Floxuridine; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Platinum; Treatment Outcome | 2005 |
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Lung Neoplasms; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Female; Floxuridine; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Single Nucleotide | 2010 |
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Topics: Activation, Metabolic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytidine Triphosphate; Deamination; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Leukocytes, Mononuclear; Phosphorylation; Uridine Triphosphate | 2018 |
38 other study(ies) available for floxuridine and 2',2'-difluoro-2'-deoxyuridine
| Article | Year |
|---|---|
Determination of the antimetabolite Gemcitabine (2',2'-difluoro-2'-deoxycytidine) and of 2',2'-difluoro-2'-deoxyuridine by 19F nuclear magnetic resonance spectroscopy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Floxuridine; Fluorine; Gemcitabine; Humans; Magnetic Resonance Spectroscopy | 1993 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Urinary Tract Infections | 2000 |
In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
Topics: Adrenal Cortex Hormones; Antigens, CD34; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Floxuridine; Gemcitabine; HL-60 Cells; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Phytohemagglutinins; Stem Cells | 2003 |
An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Sensitivity and Specificity | 2003 |
Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Mass Spectrometry | 2004 |
Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
Topics: Aged; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Molecular Structure | 2004 |
Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Middle Aged; Neoplasms | 2004 |
The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Floxuridine; Humans; Radiation-Sensitizing Agents | 2006 |
Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dogs; Female; Floxuridine; Gemcitabine; Half-Life; Metabolic Clearance Rate; Tumor Cells, Cultured | 2006 |
Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dogs; Female; Floxuridine; Gemcitabine; Half-Life; Infusions, Intravenous; Tissue Distribution | 2006 |
High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media.
Topics: Bioreactors; Chromatography, High Pressure Liquid; Culture Media; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2006 |
Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Complex Mixtures; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2007 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal Outcome; Floxuridine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2008 |
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Line; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Phosphorylation | 2008 |
Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry.
Topics: Adsorption; Chromatography, Liquid; Cytostatic Agents; Deoxycytidine; Drug Residues; Floxuridine; Fluorouracil; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Linear Models; Models, Molecular; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2009 |
Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.
Topics: Acetonitriles; Bicarbonates; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Graphite; Hydrogen Peroxide; Hydrogen-Ion Concentration; Oxidation-Reduction; Porosity; Pyrimidines; Tandem Mass Spectrometry | 2009 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tandem Mass Spectrometry | 2009 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neoplasms; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Mass flows of X-ray contrast media and cytostatics in hospital wastewater.
Topics: Contrast Media; Cytostatic Agents; Deoxycytidine; Environmental Monitoring; Floxuridine; Fluorouracil; Gemcitabine; Hospitals; Medical Waste Disposal; Waste Disposal, Fluid; Water Pollutants; Water Pollution, Chemical; Water Purification; X-Rays | 2009 |
Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Deoxycytidine; Floxuridine; Gemcitabine; Half-Life; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Polyethylene Glycols; Raloxifene Hydrochloride; Tissue Distribution; Unilamellar Liposomes | 2010 |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Computer Simulation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2010 |
Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiation-Sensitizing Agents | 2011 |
Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combinatorial Chemistry Techniques; Deoxycytidine; Deoxyuridine; Embryo, Nonmammalian; Embryonic Development; Floxuridine; Gemcitabine; Humans; Tumor Stem Cell Assay; Zebrafish | 2011 |
Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.
Topics: Deamination; Deoxycytidine; Floxuridine; Gemcitabine; HeLa Cells; Humans | 2011 |
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
Topics: Animals; Antineoplastic Agents; Calibration; Cytidine Triphosphate; Deoxycytidine; Disease Models, Animal; Floxuridine; Fluorine; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Mice; Reference Standards; Tandem Mass Spectrometry | 2011 |
The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Topics: Antineoplastic Agents; Biological Transport; Deamination; Deoxycytidine; Deoxycytidine Kinase; Floxuridine; Gemcitabine; HeLa Cells; Humans; Inactivation, Metabolic; Phosphorylation; Polyphosphates; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, Liquid; Cytosol; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Mass Spectrometry; Nucleotides; Phosphorylation | 2011 |
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metabolomics; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proteomics | 2012 |
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Genetic Association Studies; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2012 |
Determination of gemcitabine and its metabolite in extracellular fluid of rat brain tumor by ultra performance liquid chromatography-tandem mass spectrometry using microdialysis sampling after intralesional chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Chemistry; Brain Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Glioma; Limit of Detection; Linear Models; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Deoxyuridine; Floxuridine; Gemcitabine; Humans; Prodrugs; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Damage; Enzyme Activation; Floxuridine; Gemcitabine; Humans; Thymidylate Synthase | 2015 |
Preanalytical Stability of Gemcitabine and its Metabolite 2', 2'-Difluoro-2'-Deoxyuridine in Whole Blood-Assessed by Liquid Chromatography Tandem Mass Spectrometry.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Tandem Mass Spectrometry | 2015 |
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Triphosphate; Deoxycytidine; Fibroblasts; Floxuridine; Gemcitabine; Humans; Liver; Liver Neoplasms; Mice; Pancreatic Neoplasms; Primary Cell Culture; Tumor Microenvironment | 2018 |
Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Floxuridine; Fluorescent Dyes; Gemcitabine; Heterografts; Humans; Indoles; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Surface Properties; Theranostic Nanomedicine; Tissue Distribution | 2017 |
Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.
Topics: Chromatography, Liquid; Clinical Trials, Phase I as Topic; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Mice; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |